Overall survival of patients with AML/MDS-EB by CK. Overall survival of patients with mutant TP53 AML/MDS-EB by CK (n = 220) (A) and for mutant TP53 AML/MDS-EB patients who received allogeneic HSCT (n = 59) (B). Of note, the survival time starts at the date of transplant. (C) Overall survival of patients with AML/MDS-EB by CK and mutant TP53 status (n = 2101).